RAD51 and Miyoshi myopathy: MM-cell reliance on RAD51-dependent HR repair, to survive genotoxic and/or replicative stresses, could be clinically exploited for synthetic lethality or to widen the therapeutic-dose window, by combining DNA damaging agents such as DOX with inhibitors of HR repair.